Cite

    Angela Sinn et al.. “A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.” British journal of clinical pharmacology, vol. 88, no. 3, 2022, pp. 1063–1073. http://access.bl.uk/ark:/81055/vdc_100152285973.0x00004f